Related Experiment Video

Updated: Jul 7, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

The potential role of mTOR inhibitors in non-small cell lung cancer

Cesare Gridelli1, Paolo Maione, Antonio Rossi

  • 1Division of Medical Oncology, S.G. Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy. cgridelli@libero.it

The Oncologist
|February 29, 2008
PubMed

Insights

Mammalian target of rapamycin (mTOR) inhibitors show promise in treating non-small cell lung cancer (NSCLC). These drugs, while causing manageable side effects, have demonstrated antitumor activity, including regressions and stable disease in patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The mammalian target of rapamycin (mTOR) pathway regulates cellular growth and proliferation.
  • mTOR is a key mediator in the phosphatidylinositol 3-kinase/Akt signaling pathway.
  • Dysregulation of mTOR signaling is implicated in various cancers.

Purpose of the Study:

  • To review the role of mTOR inhibitors in non-small cell lung cancer (NSCLC).
  • To discuss the current clinical trial data and future directions for mTOR inhibitors in NSCLC treatment.

Main Methods:

  • Review of preclinical and clinical data on mTOR inhibitors.
  • Analysis of safety and efficacy profiles of mTOR inhibitors in cancer patients.
  • Exploration of the mTOR pathway structure and its relevance to NSCLC.

Main Results:

  • mTOR inhibitors (rapamycin analogues) induce G1 cell-cycle arrest.
  • Common toxicities include skin reactions, stomatitis, myelosuppression, and metabolic abnormalities, which are reversible.
  • Antitumor activity observed includes tumor regressions and prolonged stable disease in various malignancies, including NSCLC.

Conclusions:

  • mTOR inhibitors demonstrate promising preliminary clinical efficacy in NSCLC patients.
  • Further research and clinical development of mTOR inhibitors for NSCLC are warranted.
  • Understanding the mTOR pathway is crucial for optimizing cancer therapy.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...